Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : MNOV save search
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
Published: 2024-04-02 (Crawled : 23:00) - globenewswire.com
MNOV | $1.33 -3.73% 8K
|
Health Technology
|
| O: 2.01%
H: 4.61%
C: 0.0%
mn-166 presentation meeting trial results glioblastoma
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
Published: 2024-03-26 (Crawled : 23:00) - globenewswire.com
MNOV | $1.33 -3.73% 8K
|
Health Technology
|
| O: 2.21%
H: 5.76%
C: 5.76%
mn-166 patent japan macular treatment
MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society
Published: 2024-03-20 (Crawled : 23:00) - globenewswire.com
MNOV | $1.33 -3.73% 8K
|
Health Technology
|
| O: 2.7%
H: 2.67%
C: 0.2%
mn-001 presentation meeting
MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
Published: 2024-03-12 (Crawled : 11:00) - biospace.com/
MNOV | $1.33 -3.73% 8K
|
Health Technology
|
| O: 2.17%
H: 2.12%
C: -0.71%
mn-166 lung meeting results
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China
Published: 2024-01-17 (Crawled : 11:00) - globenewswire.com
MNOV | $1.33 -3.73% 8K
|
Health Technology
|
| O: 0.0%
H: 0.66%
C: -1.32%
mn-166 patent macular treatment grant china
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology
Published: 2023-12-21 (Crawled : 23:00) - globenewswire.com
MNOV | $1.33 -3.73% 8K
|
Health Technology
|
| O: 1.35%
H: 0.0%
C: -2.67%
mn-166 lung presentation meeting
MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe
Published: 2023-12-06 (Crawled : 23:00) - globenewswire.com
MNOV | $1.33 -3.73% 8K
|
Health Technology
|
| O: 0.0%
H: 4.17%
C: 4.17%
mn-166 europe patent treatment grant
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology
Published: 2023-11-19 (Crawled : 00:00) - globenewswire.com
MNOV | $1.33 -3.73% 8K
|
Health Technology
|
| O: 11.8%
H: 8.54%
C: 3.52%
mn-166 meeting trial results glioblastoma
MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria
Published: 2023-10-27 (Crawled : 05:00) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -18.18%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -15.73%
H: 0.0%
C: 0.0%
MNOV | $1.33 -3.73% 8K
|
Health Technology
|
| O: 0.52%
H: 0.0%
C: -1.54%
treatment phenylketonuria therapy
MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada
Published: 2023-10-10 (Crawled : 23:00) - globenewswire.com
MNOV | $1.33 -3.73% 8K
|
Health Technology
|
| O: 1.15%
H: 1.15%
C: -1.14%
mn-166 patent riluzole sclerosis treatment canada
MediciNova Receives Gene Therapy Milestone Payment
Published: 2023-10-04 (Crawled : 23:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
MNOV | $1.33 -3.73% 8K
|
Health Technology
|
| O: 1.01%
H: 2.0%
C: -0.5%
payment therapy milestone
MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
Published: 2023-09-27 (Crawled : 23:00) - globenewswire.com
MNOV | $1.33 -3.73% 8K
|
Health Technology
|
| O: 6.22%
H: 7.21%
C: -4.5%
lung contract medical results
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology
Published: 2023-08-17 (Crawled : 23:00) - globenewswire.com
MNOV | $1.33 -3.73% 8K
|
Health Technology
|
| O: -1.14%
H: 3.95%
C: 1.32%
mn-166 presentation meeting glioblastoma
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe
Published: 2023-08-16 (Crawled : 23:00) - globenewswire.com
MNOV | $1.33 -3.73% 8K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -6.63%
mn-166 europe patent macular treatment grant
MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe
Published: 2023-08-15 (Crawled : 23:00) - globenewswire.com
MNOV | $1.33 -3.73% 8K
|
Health Technology
|
| O: 6.93%
H: 2.83%
C: 0.0%
mn-001 europe patent sclerosis treatment
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe
Published: 2023-08-14 (Crawled : 23:00) - globenewswire.com
MNOV | $1.33 -3.73% 8K
|
Health Technology
|
| O: 0.84%
H: 0.0%
C: -3.75%
mn-001 europe patent treatment grant nash
MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting
Published: 2023-06-29 (Crawled : 10:00) - globenewswire.com
MNOV | $1.33 -3.73% 8K
|
Health Technology
|
| O: 0.89%
H: 1.76%
C: 0.88%
mn-166 alcohol presentation research meeting trial results
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe
Published: 2023-05-14 (Crawled : 00:00) - globenewswire.com
MNOV | $1.33 -3.73% 8K
|
Health Technology
|
| O: 1.85%
H: 2.27%
C: 0.23%
mn-166 europe patent infection grant
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada
Published: 2023-04-30 (Crawled : 00:00) - globenewswire.com
MNOV | $1.33 -3.73% 8K
|
Health Technology
|
| O: 1.42%
H: 2.8%
C: -2.34%
mn-001 patent treatment canada nash
MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
Published: 2023-03-09 (Crawled : 00:00) - globenewswire.com
MNOV | $1.33 -3.73% 8K
|
Health Technology
|
| O: 0.0%
H: 4.15%
C: 3.23%
mn-166 lung extension medical contract
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.